Introduction
Iran, a Middle Eastern country, is facing a rapidly growing HIV/AIDS epidemic in particular among injecting drug users (IDUs). Since 1987, more than 6700 cases of HIV/ AIDS have been reported in Iran. Of 4606 cases with a known transmission route, 85% were IDUs and 10% reported acquiring the infection through sexual contact [1] . Reports show that the number of people with HIV/AIDS has been sharply increasing in recent years [2] and the estimate in 2004 indicates that more than 30 000 people with HIV/AIDS are living in Iran [3] .
Although narcotic use in the form of opium smoking has a centuries-old tradition in Iran, the alarming increase in heroin injecting is a recent phenomenon. According to the rapid situation assessment conducted by Razzaghi et al. in 1999 , there were at least 166 000 IDUs in Iran [4] . The epidemic of drug use in Iran and its changing pattern should not only be examined at a national level but also in the wider regional context in that Iran's neighboring country, Afghanistan is one of the main producers of opium in the world [5] and drugs have been heavily trafficked to and through Iran to other countries [6] .
Drug-related offences are also numerous, as a report in 2001 showed that over 300 000 individuals were arrested on drug-related charges and the number of people convicted of drug-related offences constitutes 47% of the total prison population in Iran [6] . In addition, according to the rapid situation assessment in 1999, drug use including heroin injection was not rare among incarcerated drug users [4] .
Although Iran is a predominantly Islamic country, it has adopted harm-reduction policies for drug users. Under this policy, the Ministry of Health has started a number of programs for tackling the HIV epidemic among IDUs, some in collaboration with prison authorities [7] . In particular, methadone maintenance therapy (MMT), and needle/syringe exchange programs have been established in many provinces. Nonetheless, there is no available data on HIV-1 prevalence or the risk characteristics of drug users in Iran. This study which is a part of a large socio-epidemiological project called HADI (HIV/AIDS Prevention Study among Drug Users in Iran) aims to define HIV-1 prevalence and examine the associated factors for HIV-1 infection among a group of drug users in Tehran.
Methods

Participants and settings
Between late October 2003 and mid May 2004, drug users attending three public out-patient drug treatment centers in Tehran were consecutively recruited into the study. Drug users were eligible for participation if they had used illicit drugs during the previous month, and were seeking drug treatment for the first time in those centers. There was no age restriction on interview respondents although the treatment services targeted adults. The recruitment sites were public drug treatment centers each representing a subdivision of out-patient health facilities for drug users organized by the Ministry of Health or the State Welfare Organization. In the treatment center of the State Welfare Organization, detoxification and relapse prevention medical treatment and counseling were provided at affordable costs. The second study site was a so-called triangular clinic where a number of services were available free of charge including HIV testing and counseling, needle exchange, and MMT [8] ; however, in the present study, drug users seeking drug treatment were recruited. In the third center, MMTand detoxification services were provided at affordable costs.
Data collection
After obtaining written informed consent, each respondent was confidentially interviewed by an experienced interviewer using a structured questionnaire. All interviews were conducted in Persian language. Interviewers (two males and one female in each center) were re-trained for this study in two separate sessions.
The questionnaire was developed from a questionnaire produced by Family Health International for use with IDUs [9] . Modifications to the original questionnaire were made following the findings of the preliminary qualitative study (conducted among 19 drug users in late 2002). In May 2003, the revised questionnaire was pre-tested among 52 drug users to assess sample size calculation, 22 respondents were re-interviewed after 3 days using the same questionnaire to test for its reliability and those questions producing inconsistent answers were excluded. The final questionnaire included 80 questions.
HIV-1 testing
On completion of the 20-min interview, consented participants were counseled and then the trained interviewer took an oral mucosal transudate sample. In addition to information given during the counseling, participants received an educational pamphlet and a confidential code for receiving oral HIV-1 test result.
Oral samples were obtained using the OraSure oral fluid specimen collection device (OraSure Technologies, Inc., Beaverton, Oregon, USA). Collected samples were kept cool until being shipped in batches to Nagoya City University of Japan for testing. All samples were tested for HIV-1 with enzyme-linked immunosorbent assay (ELISA) (Oral Fluid Vironostika HIV-1 Microelisa System; BioMérieux Inc, Durham, North Carolina, USA). Repeatedly reactive ELISA samples were confirmed using a western blot test (OraSure HIV-1 Western Blot Kit; OraSure Technologies, Inc.) [10] .
Ethical issues
This research's protocol was approved by the Ethics Committee in Medical Sciences Research in the Ministry of Health in Iran and by the Committee for Research on Human Subjects at Kyoto University in Japan. Separate informed consents were obtained for the interview and HIV testing, and no personal identifier was recorded on the questionnaires. All participants were given advice recommending them to undertake free serum HIV-1 testing for final clinical diagnosis, however, the results of the oral test were provided for participants upon request.
Statistical analysis
Statistical analysis was performed using SPSS for Windows (version 12.01; SPSS Inc., Chicago, Illinois, USA). Bivariate analyses were performed to determine associations between HIV-1 status and self-reported characteristics, followed by logistic regression analyses. Variables were entered into a multivariate model if their association with HIV-1 infection by bivariate analysis had a P value 0.10 or if they were considered epidemiologically important. A multivariate model was used to obtain adjusted odds ratio (OR) and 95% confidence interval (CI) for the associated factors with HIV-1 infection.
Results
During the study period, 611 (588 male and 23 female) eligible drug users visited study sites and all agreed to be interviewed. Three male participants (0.5%) refused to provide oral specimens and 30 specimens (5%) were insufficient for laboratory analysis. Because of the small number of female participants, only males were considered for further statistical analysis. Of 555 available male specimens, 46 were confirmed positive for HIV-1 antibodies using the western blot test and the remainder (consisting of 493 negative and 16 indeterminate cases) were classified negative for statistical analysis.
The participants were categorized as an IDU if they reported ever injected an illicit drug in their lifetime and as non-IDU if they reported never injecting an illicit drug. HIV-1 prevalence was 15.2% among 165 male IDUs and 5.4% among 390 male non-IDUs. Five out of 23 female drug users were IDU, and only one female IDU was found to be HIV-1 positive.
Two thirds of males reported being treated elsewhere for drug use before their first time visit to one of the study sites. As there was no difference in HIV-1 prevalence or risk characteristics between drug users who had been treated and those who had not, the cumulative data for these two groups are presented in this paper. Table 1 shows the detailed sociodemographic characteristics of both IDUs and non-IDUs. Among the sociodemographic characteristics of the IDUs, only joblessness was marginally associated with HIV-1 infection in the bivariate analysis (P ¼ 0.058). None of the sociodemographic characteristics of non-IDUs was associated with HIV-1 infection.
Sociodemographic characteristics
Associated factors with HIV-1 infection among male IDUs
The median age for commencement of drug injection was 25.0 years old and during the month prior to the interview, heroin was the main drug used by 72% of IDUs (not shown in the table). One-third reported ever injected a drug using a shared injection utensil, of which 62% had used a shared needle/syringe only outside prison and up to 38% had ever injected a drug using a shared injection utensil (needle/syringe or handmade device) inside prison (Table 2 ).
There was no significant difference in HIV-1 prevalence by age at first injection, by length of injection, or by time elapsing from last injection. However, total length of lifetime incarcerations found to be associated with higher prevalence of HIV-1 infection in a dose-dependent manner as the odds ratio increased from 3.24 among IDUs who had experienced incarceration of less than 6 months to 8.38 in those who had been incarcerated for 6 months or more compared with those who had never been incarcerated. Those IDUs with a history of shared injection inside prison had a much higher HIV-1 prevalence in comparison with those who had never had a shared injection (OR, 10.00; 95% CI, 3.23-30.94), whereas HIV-1 prevalence among IDUs with a history of shared injection only outside prison was not significantly higher than those who had never shared (P ¼ 0.099).
No association was found between HIV-1 infection and any variables related to sexual behaviour of IDUs, levels of HIV/AIDS knowledge, levels of perceived HIV risk, history of tattooing or previous HIV testing.
Associated factors for HIV-1 infection among male non-IDUs
During the month prior to interviewing, opium was the main drug used by 84% of non-IDUs. HIV-1 prevalence was significantly higher among those non-IDUs who had never used a condom during sex (13 of 155; 8.4%) than those who had (6 of 205; 2.9%) (OR, 3.03; 95% CI, 1.12-8.18). HIV-1 infection was marginally higher among those who perceived their risk of getting HIV through unprotected sex to be very low or low (9 of 111; 8.1%) compared to those non-IDUs who reported their risk to be intermediate to very high (6 of 188; 3.2%) (P ¼ 0.060). Furthermore, HIV-1 prevalence was significantly higher among those who specifically did not know that condoms can prevent HIV/STD (11 of 88; 12.5%) than those who did (10/302; 3.3%) (OR, 4.17; 95% CI, 1.70-10.18). However, HIV-1 infection was not associated with a history of incarceration, the number of lifetime sexual partners, a history of monetary exchange for sex, levels of general HIV/AIDS knowledge, history of tattooing or experience of previous HIV testing.
Multivariate analysis
In the multivariate analysis conducted on the data for male IDUs controlling for basic demographics, a history of shared injection inside prison remained the major factor associated with HIV-1 infection (adjusted OR, 12.37; 95% CI, 2.94-51.97) ( Table 3) . With the limited sample size in our study, a history of shared injection in settings other than prison was not found to be significantly associated with the infection. Two variables of total length of incarcerations and length of lifetime injection were entered into the model to control for length of exposure [11] . No interaction was found between the length of incarceration and sharing practice in association with HIV infection.
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remained significantly associated with HIV-1 infection (adjusted OR, 3.42; 95% CI, 1.25-9.36).
Discussion
Despite the increasing number of HIV/AIDS cases in Middle Eastern countries, there have been few epidemiological studies to provide evidence regarding the prevalence of HIV infection and characteristics of at-risk populations in this region [12] . In the present study, we investigated HIV-1 prevalence and risk characteristics of IDUs and non-IDUs who had visited drug treatment centers in Tehran, Iran. We found that HIV-1 infection was already prevalent among both groups at alarming levels. Among IDU participants, infection was strongly associated with a history of shared drug injection inside prison, whereas it was not significantly associated with shared drug injection outside prison. The increased risk of HIV infection among incarcerated drug users has been reported from several other countries [13] [14] [15] [16] [17] [18] , and similar findings have been reported from Thailand, where drug injecting inside prison was shown to be an important correlate of HIV infection among incarcerated drug users [19] . The stronger association of HIV-1 infection with sharing practices inside prison rather than outside of prison in Iran might be related to a shorter supply of needles/syringes inside prison that may have led to more frequent sharing practice with a greater number of people inside prison and using handmade injecting devices. Although this finding is quite alarming, it also indicates that there are still good opportunities to stop the spread of HIV infection within prison and in the broader IDU and general population outside prisons in Iran.
Our bivariate analysis showed that there is a dosedependent relationship between HIV-1 infection and the length of lifetime incarceration among IDU participants. This is an important consideration in view of the current situation in Iran with huge and growing numbers of drug users and high rates of arrests and incarcerations due to drug-related offences [6] . Although there are reports indicating a tendency for reforms toward non-penal legislations for drug use in Iran [20, 21] , our findings strongly suggest that preventive interventions are compelling now for incarcerated drug users to ensure their safe passage throughout incarceration. While legal restrictions are a barrier to distributing clean needles/ syringes within the prison system in Iran, other practical interventions such as MMT [22] [23] [24] , voluntary HIV testing and counseling, and extensive educational programs that have been started in some prisons should be swiftly scaled-up. Meanwhile, community-based prevention interventions including MMT and needle/ syringe exchange programs [25] [26] [27] that are now being extended in Iran [7] are of great importance for tackling the HIV epidemic among drug users.
Our study further indicated the possible threat of bridging HIV-1 infection from IDUs to their partners through sexual contact [28] [29] [30] as many IDUs had multiple sexual partners in their lifetime and exchanging money for sex was not uncommon. In addition, condom use does not seem to be well adopted by IDUs as only 53% of sexually active IDUs reported ever using a condom. It is also important to note that even among those IDUs who ever used a condom, consistent use was not common as only 37% of them used a condom during their last sexual experience.
Our findings show that the lack of condom use is the only behavioral factor associated with the greater prevalence of HIV-1 infection among non-IDUs. Accompanied by the low risk perception and poor knowledge about the efficacy of condoms in preventing HIV/STD among HIV-positive non-IDUs, this finding may suggest that low risk perception or poor knowledge led to less protected sexual behaviors and thereby to acquisition of HIV-1.
Although we were not able to specify the type of sexual contact (homosexual or heterosexual) in this survey, it remains an important research question to be answered in future studies. Meanwhile, there is a theoretical possibility that some of the HIV-positive IDUs with unprotected sexual behaviors were misclassified in the non-IDU group due to the social undesirability of revealing a history of drug injecting [31, 32] , this is, however unlikely because the demographics and general drug use characteristics (including age, marital status, and age at first drug use) which were significantly different between IDU and non-IDU respondents, were similar between HIV-positive and HIV-negative non-IDU participants.
Finally, the present study has some limitations. First, our participants are unlikely representative of the general drug using population as they were recruited from only three treatment centers in Tehran. Furthermore, our study was mostly based on the self-reported information gained from interviews, which could be biased by the participants recall ability under the influence of drugs. Our failure to assess condom use differentiating homosexual and heterosexual sex may have introduced some confounding into the analysis of sexual risk of HIV infection among both IDUs and non-IDUs. There are also several unanswered questions about the risk behaviours of drug users such as condom use with different sexual partners, and details of shared injection which require further investigation.
In conclusion, our findings strongly suggest that drug injection inside prison carries a particular risk for HIV infection and that HIV infection among IDUs is likely to be bridged to the broader population through sexual contact without strong prevention programs. Although Iran has started its HIV-related programs to strengthen HIV surveillance and to introduce harm reduction programs among IDUs, such programs should be urgently extended nationwide and integrated with a condom promotion program to prevent sexual transmission of HIV to/from drug users.
